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Peer review under rwww.sciencedirect.comEditorialBile acids have been traditionally viewed as detergent molecules
involved in the solubilization and absorption of lipids and lipid-
soluble vitamins from the intestines. However, as a result of
intensive research over the past two decades, bile acids are now
viewed as endocrine signaling molecules that activate speciﬁc
nuclear receptors and G-protein coupled receptors regulating
nutrient metabolism in the liver and intestines. The year 2015
marks the 20-year anniversary of the cloning and discovery of
farnesoid X receptor (NR4H1; FXR). FXR is a main bile acid
nuclear receptor and plays an essential role in the regulation of bile
acids, lipids, glucose and drug metabolism, as well as inhibiting
inﬂammation and suppressing carcinogenesis in the liver and
intestine. Bile acids also activate pregnane X receptor, constitutive
androstane receptor, vitamin D receptor, G protein–coupled bile
acid receptor (TGR5), and sphingosine-1-phosphate receptor 2
(S1PR2) to regulate growth and functions of hepatocytes, cholan-
giocytes and enterocytes. Moreover, bile acids also induce, via
FXR, critical regulators of metabolism, inﬂammation and carcino-
genesis in the liver and intestine, including small heterodimer
partner (SHP) and ﬁbroblast growth factor 15/19 (FGF15/19). Theory
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promoter regulation, posttranscriptional modulation and epigenetic
regulation.
Historically, bile acids have been used as medicines around the
world. Identiﬁcation of new signaling pathways mediated by bile
acids and bile acid derivatives should result in optimizing the
current standard therapy for hepatic disorders and developing
novel therapeutic targets for various liver diseases and metabolic
syndrome.
In this issue, we have gathered leading experts in bile acid
research around the world to provide the most comprehensive and
timely review of bile acids, their receptors and regulated pathways/
functions with a focus on liver and the gastrointestinal area. These
in-depth reviews will provide the researchers, clinicians and
pharmaceutical entrepreneurs the background knowledge for
targeting bile acid–mediated signaling pathways to prevent and
treat hepatic, intestinal, and metabolic disorders.Grace L. Guo, Huiping ZhouCBAs and insulin activates phosphoinositide-dependent protein kinase
1 (PDK1), which activates protein kinase C ζ (PKCζ). PKCζ then
phosphorylates the farnesoid X receptor (FXR) allowing it to translocate
to the nucleus. FXR is activated by bile acids causing the induction of a
number of genes involved in bile acid metabolism and transport. Bile
Medica, Chinese Academy of Medical Sciences. Production and hosting by
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acids induce the gene encoding the short heterodimeric partner (SHP).
SHP is a nuclear receptor, without a DNA binding domain, and
functions much like a dominant-negative protein by interacting with
other nuclear receptors (HNF4α, LRH-1 and others) to inhibit their
functions. HNF4α is also an important regulator of nutrient metabolism
in the liver. PKCζ also regulates the movement of the basolateral bile
acid transporter (NTCP) and canalicular membrane transporter (BSEP)
to their respective membranes. Activated AKT increases glycogen
synthesis and inhibits glucose synthesis by down-regulating the genes
encoding the gluconeogenic genes, PEPCK and G-6-Pase, and activat-
ing glycogen synthase activity, respectively. S1PR2 also activates
nuclear sphingosine kinase 2 (SphK2) increasing the concentration of
S1P in the nucleus, a powerful inhibitor of histone deacetylase 1 and 2
(HDAC 1/2). Inhibition of HDAC 1/2 allows for increased histone
acetylation and increased differential induction of genes encoding
enzyme and nuclear receptors involved in regulating nutrient metabo-
lism in the liver. In this manner, bile acids function as nutrient signaling
molecules in the liver to regulate metabolism.
Model for the role of sphingosine 1-phosphate receptor 2 in
regulating nutrient metabolism in the liver. Abbreviations: S1PR2,
sphingosine-1-phosphate receptor 2; TCA, taurocholate; Src, Src
kinase; EGFR, epidermal growth factor receptor; PI3K, phosphoi-
nositide-3-kinase; PKCζ, protein kinase C zeta; PPARα, peroxi-
some proliferator-activated receptor alpha; FXR, farnesoid X
receptor; SHP, short heterodimeric partner; NTCP, Naþ/taurocho-
late co-transporting polypeptide; BSEP, bile salt export pump; PC,
phosphotidylcholine; PEPCK, phosphoenolpyruvate carboxykinase;
G-6-Pase, glucose-6-phosphatase; PDK1, phosphoinositide-dependent
protein kinase 1; AKT, protein kinase B; SREBP, sterol regulatory
element-binding protein.
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